Middle East Pharmaceutical Industries Company (TADAWUL:4016)
Saudi Arabia flag Saudi Arabia · Delayed Price · Currency is SAR
98.25
+1.05 (1.08%)
Mar 24, 2026, 10:55 AM AST

TADAWUL:4016 Income Statement

Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
460.48394338.44302.66287.22
Revenue Growth (YoY)
16.87%16.42%11.82%5.38%-4.79%
Cost of Revenue
174.71151.59134.74119.21113.47
Gross Profit
285.78242.41203.7183.45173.76
Selling, General & Admin
177.35150127.59113.7397.74
Other Operating Expenses
0.02-0.420.090.18-0.14
Operating Expenses
178.84153.12126.17114.0497.6
Operating Income
106.9389.2977.5369.4176.16
Interest Expense
-3.25-3.67-5.75-4.73-1.87
Currency Exchange Gain (Loss)
0.02-0.04-0.470.27-
Other Non Operating Income (Expenses)
-----1.08
EBT Excluding Unusual Items
103.785.5871.3164.9573.22
Gain (Loss) on Sale of Investments
-----2.76
Gain (Loss) on Sale of Assets
0.040.120.130.08-
Pretax Income
103.7486.3571.4465.0270.46
Income Tax Expense
6.736.55.615.574.18
Net Income
97.0179.8565.8359.4566.28
Net Income to Common
97.0179.8565.8359.4566.28
Net Income Growth
21.49%21.30%10.72%-10.31%-8.97%
Shares Outstanding (Basic)
2020202020
Shares Outstanding (Diluted)
2020202020
EPS (Basic)
4.853.993.292.973.31
EPS (Diluted)
4.853.993.292.973.31
EPS Growth
21.49%21.30%10.72%-10.31%-8.97%
Free Cash Flow
73.7421.9171.8258.9925.28
Free Cash Flow Per Share
3.691.093.592.951.26
Dividend Per Share
-2.000---
Gross Margin
62.06%61.52%60.19%60.61%60.50%
Operating Margin
23.22%22.66%22.91%22.93%26.52%
Profit Margin
21.07%20.27%19.45%19.64%23.08%
Free Cash Flow Margin
16.01%5.56%21.22%19.49%8.80%
EBITDA
119.1299.0885.1476.2582.86
EBITDA Margin
25.87%25.15%25.16%25.19%28.85%
D&A For EBITDA
12.199.87.616.846.7
EBIT
106.9389.2977.5369.4176.16
EBIT Margin
23.22%22.66%22.91%22.93%26.52%
Effective Tax Rate
6.49%7.53%7.85%8.57%5.93%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.